Comparing Remimazolam and Propofol for Postoperative Anesthesia Satisfaction in Outpatient Gynecological Surgery: A Randomized Clinical Trial
Xu-Lin Wang,Ling-Ling Dai,Yan-Na Li,Jian-Wen Zhang,Ming-Cui Qu,Yao-Yao Zhou,Na Xing
DOI: https://doi.org/10.2147/dddt.s483029
IF: 4.3188
2024-10-19
Drug Design Development and Therapy
Abstract:Xu-Lin Wang, 1, &ast Ling-Ling Dai, 2, &ast Yan-Na Li, 1 Jian-Wen Zhang, 1 Ming-Cui Qu, 1 Yao-Yao Zhou, 1 Na Xing 1 1 Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China; 2 Department of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Na Xing, Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, People's Republic of China, Tel +8613949095172, Email Purpose: This study aimed to compare the efficacy of remimazolam and propofol regarding postoperative anesthesia satisfaction in patients undergoing outpatient gynecological surgery. Patients and Methods: This was a single-center, open-label, non-inferiority, randomized clinical trial. Patients aged ≥ 18 years who underwent outpatient gynecological surgery with sedation were enrolled. Participants were randomly assigned to be sedated with remimazolam or propofol. The primary endpoint was the immediate postoperative anesthesia satisfaction score, evaluated through the Iowa Satisfaction with Anesthesia Scale (ISAS). Results: 168 patients were randomly allocated to either the remimazolam group (n = 84) or the propofol group (n = 84). The mean (standard deviation) ISAS scores immediately after surgery were 1.7 (0.6) for the remimazolam group and 2.0 (0.7) for the propofol group (difference, – 0.2; 97.5% confidence interval [CI]: – 0.5 to – 0.0; p = 0.02), indicating non-inferiority. The length of post-anesthesia care unit (PACU) stay was longer in the remimazolam group than in the propofol group (27.6 [9.1] min vs 22.4 [7.0] min; difference, 5.2 [95% CI: 2.7 to 7.6] min; p < 0.001). High-intensity injection pain was less frequently observed in the remimazolam group than in the propofol group (3.6% vs 45.2%; difference, – 41.7% [95% CI: – 54.2% to – 29.1%]; p < 0.001). The nausea score was higher in the remimazolam group immediately after surgery than in the propofol group. Pain, nausea, sleep quality, anxiety, and depression scores were higher in the remimazolam group than in the propofol group on postoperative day 1. The incidence of adverse events and other secondary endpoints was comparable between the two groups. Conclusion: Remimazolam was non-inferior to propofol regarding postoperative anesthesia satisfaction in patients undergoing outpatient gynecological surgery. Therefore, it should be considered as a new sedation alternative in such procedures. Keywords: remimazolam, propofol, patient satisfaction, outpatient gynecological surgery, sedation Increasingly, there has been a noticeable trend towards performing minor gynecological surgeries in outpatient settings, driven by the goals of cost-effectiveness, patient convenience, faster recovery, and reduced risks of infections and respiratory complications. 1 Effective pain management in such surgery is crucial for ensuring both the safe and successful performance of procedures and patient comfort, which are the primary objectives of outpatient gynecological surgery. 2 Despite the availability of various analgesic modalities, including local anesthesia, oral or intravenous analgesics, sedation, and general anesthesia, 3–5 many patients still experience moderate to severe pain during these surgeries. 3,5 Research suggests that deep sedation might be a better choice for this population and associated with a reduced incidence of anesthesia-related complications. 4,6–8 Currently, sedative drug options for outpatient gynecological surgery are scarce. Due to its rapid onset, short half-life, and swift recovery, propofol stands as the preferred sedative for outpatient procedures. 9,10 It is effectively used in conjunction with opioids for sedation in outpatient gynecological surgeries, including dilation and curettage, hysteroscopic examinations, and hysteroscopic surgeries. 6,11–13 However, its use raises significant concerns regarding adverse reactions, including hypotension, hypoxemia, and injection pain. 14,15 Moreover, midazolam, another commonly used sedative, carries a reduced risk of hypotension or respiratory depression compared to propofol. Nevertheless, its slow onset and prolonged half-life result in delayed emergence, which might not be ideal for short outpatient procedures. 16,17 Therefore, it is of utmost importance to investigate novel sedative -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal